Skip to content

NBlaz – Lifestyle

Author: Synendos Therapeutics AG

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

May 20, 2026

All content ©2025 Tork Media
All Rights Reserved. For more information on this site, please read our Privacy Policy, Terms of Service, Cookie Policy, and Ad Choices.